FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
Efficacy was evaluated using real-world data from the EPIK-P1 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1647 results
NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted Therapies in Paediatric and Young Adult Patients with Refractory Cancers
Findings from the NCI-COG Pediatric MATCH screening Protocol
FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable or Metastatic Melanoma
Evidence for efficacy is based on results from the RELATIVITY-047 study
Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Subgroup analysis by PD-L1 combined positive score in KEYNOTE-048 study
Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in Patients with Previously Treated Progressive Classical Kaposi Sarcoma
Findings from the single-arm phase II study
EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS ≥1
New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer
Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer Maintained with a Long-Term Analysis
Long-term outcomes and exploratory analyses from the BILCAP study
FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with dMMR in solid tumours
BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy are at Increased Risk of Peritoneal Carcinomatosis
The risk to develop peritoneal carcinomatosis increases over time
ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to Identify Patients Who May Benefit from Further Therapeutic Intervention
Detection of ctDNA using sensitive personalised assays can inform patient prognosis and help guide patient treatment
EMA Recommends Granting a Marketing Authorisation for Tebentafusp
It is intended for the treatment of adult patients with unresectable or metastatic HLA A*02:01 positive uveal melanoma
Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival in Patients with Stage III Colon Cancer
Findings from a post-hoc analysis of IDEA-France